West China Journal of Stomatology ›› 2020, Vol. 38 ›› Issue (5): 489-494.doi: 10.7518/hxkq.2020.05.003
Previous Articles Next Articles
Received:
2020-03-08
Revised:
2020-07-18
Online:
2020-10-01
Published:
2020-10-14
Contact:
Guo Wei
E-mail:guoweicn@sohu.com
Supported by:
CLC Number:
Guo Wei. Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer[J]. West China Journal of Stomatology, 2020, 38(5): 489-494.
Add to citation manager EndNote|Ris|BibTeX
Tab 1
Results of immunotherapy with anti-PD-1 monoclonal antibody in patients with recurrent/metastatic head and neck cancer
姓名 | 性别 | 年龄/岁 | 诊断 | 用药次数 | 近期疗效 |
---|---|---|---|---|---|
孙XX | 男 | 52 | 肺癌舌转移 | 4 | 疾病稳定 |
王X | 男 | 35 | 右下牙龈黑色素瘤远处转移 | 1 | 死亡 |
熊XX | 男 | 59 | 左腮腺癌颈部转移 | 3 | 死亡 |
刘XX | 女 | 52 | 左颌下腺腺样囊性癌肺部转移 | 6 | 疾病稳定 |
宋XX | 女 | 65 | 下牙龈黏膜黑色素瘤肺部转移 | 5 | 疾病稳定 |
张XX | 女 | 42 | 颌骨肉瘤术后、放疗后复发 | 4 | 疾病进展 |
陶XX | 男 | 47 | 腮腺导管癌术后放疗后骨转移 | 6 | 疾病进展 |
尹XX | 男 | 57 | 颞部鳞状细胞癌多次术后复发 | 4 | 完全缓解 |
徐XX | 男 | 49 | 鼻腔鼻窦恶性黑色素瘤远处转移 | 4 | 疾病稳定 |
苏XX | 女 | 35 | 上前牙龈恶性黑色素瘤颈部转移 | 12 | 部分缓解 |
[1] |
Cramer JD, Burtness B, Ferris RL . Immunotherapy for head and neck cancer: recent advances and future directions[J]. Oral Oncol, 2019,99:104460.
doi: 10.1016/j.oraloncology.2019.104460 URL pmid: 31683169 |
[2] |
Burtness B, Harrington KJ, Greil R , et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019,394(10212):1915-1928.
doi: 10.1016/S0140-6736(19)32591-7 URL pmid: 31679945 |
[3] |
Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867.
doi: 10.1056/NEJMoa1602252 URL pmid: 27718784 |
[4] |
Cohen EEW, Soulières D, Le Tourneau C , et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393(10167):156-167.
doi: 10.1016/S0140-6736(18)31999-8 URL pmid: 30509740 |
[5] |
Seiwert TY, Burtness B, Mehra R , et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17(7):956-965.
doi: 10.1016/S1470-2045(16)30066-3 URL pmid: 27247226 |
[6] |
Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018,81:45-51.
doi: 10.1016/j.oraloncology.2018.04.008 URL pmid: 29884413 |
[7] |
Yearley JH, Gibson C, Yu N , et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer[J]. Clin Cancer Res, 2017,23(12):3158-3167.
doi: 10.1158/1078-0432.CCR-16-1761 URL pmid: 28619999 |
[8] |
Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128.
doi: 10.1126/science.aaa1348 URL pmid: 25765070 |
[9] |
Lawrence MS, Stojanov P, Polak P , et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes[J]. Nature, 2013,499(7457):214-218.
doi: 10.1038/nature12213 URL pmid: 23770567 |
[10] |
Gameiro SF, Ghasemi F, Barrett JW , et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy[J]. Oncoimmunology, 2018,7(10):e1498439.
doi: 10.1080/2162402X.2018.1498439 URL pmid: 30288365 |
[11] |
Harrington KJ, Ferris RL, Blumenschein G Jr , et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(8):1104-1115.
doi: 10.1016/S1470-2045(17)30421-7 URL pmid: 28651929 |
[12] |
Wang DY, Salem JE, Cohen JV , et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728.
doi: 10.1001/jamaoncol.2018.3923 URL pmid: 30242316 |
[13] |
Johnson DB, Balko JM, Compton ML , et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016,375(18):1749-1755.
doi: 10.1056/NEJMoa1609214 URL pmid: 27806233 |
[14] |
Di Giacomo AM, Danielli R, Guidoboni M , et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009,58(8):1297-1306.
doi: 10.1007/s00262-008-0642-y URL pmid: 19139884 |
[15] |
Chiou VL, Burotto M . Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015,33(31):3541-3543.
doi: 10.1200/JCO.2015.61.6870 URL pmid: 26261262 |
[16] |
Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247.
doi: 10.1016/j.ejca.2008.10.026 URL |
[17] |
Baxi SS, Dunn LA, Burtness BA . Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma[J]. Oral Oncol, 2016,62:147-148.
doi: 10.1016/j.oraloncology.2016.10.007 URL pmid: 27776933 |
[18] |
Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420.
doi: 10.1158/1078-0432.CCR-09-1624 URL pmid: 19934295 |
[19] |
Seymour L, Bogaerts J, Perrone A , et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017,18(3):e143-e152.
doi: 10.1016/S1470-2045(17)30074-8 URL pmid: 28271869 |
[20] |
Tazdait M, Mezquita L, Lahmar J , et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018,88:38-47.
doi: 10.1016/j.ejca.2017.10.017 URL pmid: 29182990 |
[21] |
Le Lay J, Jarraya H, Lebellec L , et al. irRECIST and iRECIST: the devil is in the details[J]. Ann Oncol, 2017,28(7):1676-1678.
doi: 10.1093/annonc/mdx168 URL pmid: 28383646 |
[22] |
Xiang JJ, Uy NF, Minja FJ , et al. Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report[J]. Laryngoscope, 2020,130(4):907-910.
doi: 10.1002/lary.28042 URL pmid: 31058321 |
[23] |
Champiat S, Dercle L, Ammari S , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928.
doi: 10.1158/1078-0432.CCR-16-1741 URL pmid: 27827313 |
[24] |
Saâda-Bouzid E, Defaucheux C, Karabajakian A , et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017,28(7):1605-1611.
doi: 10.1093/annonc/mdx178 URL pmid: 28419181 |
[25] |
Keam SJ . Toripalimab: first global approval[J]. Drugs, 2019,79(5):573-578.
doi: 10.1007/s40265-019-01076-2 URL pmid: 30805896 |
[26] |
Tang B, Yan X, Sheng X , et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients[J]. J Hematol Oncol, 2019,12(1):7.
doi: 10.1186/s13045-018-0693-2 URL pmid: 30642373 |
[27] |
Sheng X, Yan X, Chi Z , et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ⅰb trial[J]. J Clin Oncol, 2019,37(32):2987-2999.
doi: 10.1200/JCO.19.00210 URL pmid: 31403867 |
[28] |
Wang F, Wei XL, Wang FH , et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486.
doi: 10.1093/annonc/mdz197 URL pmid: 31236579 |
[29] |
Hoy SM . Sintilimab: first global approval[J]. Drugs, 2019,79(3):341-346.
doi: 10.1007/s40265-019-1066-z URL pmid: 30742278 |
[30] |
Markham A, Keam SJ . Camrelizumab: first global approval[J]. Drugs, 2019,79(12):1355-1361.
doi: 10.1007/s40265-019-01167-0 URL pmid: 31313098 |
[31] |
Chen X, Ma L, Wang X , et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med, 2019,16(1):173-181.
doi: 10.20892/j.issn.2095-3941.2018.0172 URL pmid: 31119058 |
[32] |
Lin C, Wang S, Xie W , et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J]. Oncotarget, 2016,7(37):59236-59244.
doi: 10.18632/oncotarget.10985 URL pmid: 27494860 |
[33] |
Xu J, Zhang Y, Jia R , et al. Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523.
doi: 10.1158/1078-0432.CCR-18-2484 URL pmid: 30348638 |
[1] | Liu Lei, Xiang Zhongzheng, Li Yi, Guo Wei, Yang Kai, Wang Jun, Sun Zhijun, Ren Guoxin, Zhang Jianguo, Sun Moyi, Ran Wei, Huang Guilin, Tang Zhangui, Li Longjiang. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus [J]. West China Journal of Stomatology, 2022, 40(6): 619-628. |
[2] | ZHI Ke-qian, XU Yan, REN Wen-hao, GAO Ling, ZHAO Lu, YANG Yong, ZHANG Yin-cheng. Killing effect of cytotoxicty T lymphocyte primed by two different methods preparation of dendritic cells pulsed with antigen on Tca8113 cells in vitro [J]. West China Journal of Stomatology, 2010, 28(02): 195-198. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||